Takahashi Toru, Komatsu Shohei, Demizu Yusuke, Arai Keisuke, Ishihara Nobuaki, Fujisawa Akihiro, Gon Hidetoshi, Toyama Hirochika, Tokumaru Sunao, Fukumoto Takumi
Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe, Hyogo, Japan.
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0026. Epub 2025 Apr 22.
Hepatocellular carcinoma (HCC) often requires repeated therapy and poses challenges in treatment selection, particularly in patients with impaired liver function. Although hepatic resection, radiofrequency ablation, and liver transplantation are standard local curative therapies, the position of radiotherapy, including proton beam therapy (PBT), remains relatively underexplored. Herein, we report an illustrative case of unresectable HCC treated with spacer placement surgery using a bioabsorbable spacer, followed by PBT.
We report the case of a 77-year-old male patient diagnosed with a 6 cm HCC in segment 8, accompanied by impaired liver function, precluding hepatic resection. PBT was planned; however, because of the proximity of the gastrointestinal tract to the tumor, spacer placement was deemed necessary, and a bioabsorbable polyglycolic acid spacer was placed, followed by PBT. Owing to the sufficient space provided by the spacer, curative doses of PBT could be delivered to the tumor, and the patient survived for 26 months after spacer placement surgery without any sign of recurrence.
Bioabsorbable spacer placement surgery and subsequent PBT are feasible and promising treatment options for unresectable HCC with impaired liver function.
肝细胞癌(HCC)常常需要反复治疗,在治疗选择方面存在挑战,尤其是对于肝功能受损的患者。虽然肝切除术、射频消融术和肝移植是标准的局部根治性治疗方法,但包括质子束治疗(PBT)在内的放射治疗的地位仍相对未得到充分探索。在此,我们报告一例不可切除的HCC患者的病例,该患者先接受了使用生物可吸收间隔物的间隔物置入手术,随后接受了PBT治疗。
我们报告一例77岁男性患者,其被诊断为肝段8有一个6 cm的HCC,伴有肝功能受损,无法进行肝切除术。计划进行PBT;然而,由于胃肠道与肿瘤位置接近,认为有必要置入间隔物,于是置入了一个生物可吸收聚乙醇酸间隔物,随后进行PBT。由于间隔物提供了足够的空间,可将PBT的根治性剂量传递至肿瘤,患者在间隔物置入手术后存活了26个月,没有任何复发迹象。
生物可吸收间隔物置入手术及随后的PBT对于肝功能受损的不可切除HCC是可行且有前景的治疗选择。